The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 04, 2022

Filed:

Apr. 20, 2018
Applicants:

Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;

Université DE Bretagne Occidentale, Brest, FR;

Etablissement Français Du Sang (Efs), La Plaine Saint Denis, FR;

Centre Hospitalier Regional ET Universitaire DE Brest, Brest, FR;

Inventors:

Pascal Trouve, Brest, FR;

Claude Ferec, Brest, FR;

Mathieu Kerbiriou, Brest, FR;

Florentin Huguet, Brest, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/40 (2006.01); A61P 11/00 (2006.01); A61K 9/00 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
A61K 31/40 (2013.01); A61K 9/007 (2013.01); A61P 11/00 (2018.01); C12N 15/1137 (2013.01); C12N 2310/11 (2013.01);
Abstract

Activating transcription factor 6 (ATF6) is involved in cystic fibrosis transmembrane conductance regulator (CFTR) repression and understanding this inhibitory mechanism is of great interest to develop a therapeutic approach based on UPR regulation. Using site-1 protease (S1P) inhibitor (e.g. PF-429242) the inventors showed that both membrane localization and function of F508del-CFTR are partially restored. Accordingly, the present invention relates to a method of treating a disease associated with reduced CFTR function in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a S1P inhibitor.


Find Patent Forward Citations

Loading…